Munich, Germany, June 15th, 2023 - Innovative Molecules GmbH, a German based drug development company focused on developing next-generation treatments for Herpes simplex virus (HSV) infections, today announced that the first subjects have received IM-250 in a Phase 1 clinical trial. The study, conducted at the University Clinic Heidelberg in Germany, evaluates the safety, tolerability, and pharmacokinetics of IM-250 in healthy volunteers.
Since the introduction of nucleoside analogues decades ago, there was no significant innovation in treatment of herpes simplex infections which reached the market. New treatment options are clearly needed for patients suffering from HSV-mediated diseases. IM-250 is a highly potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication. The compound targets the helicase-primase enzyme complex of the virus. “Due to its novel mechanism of action and optimized molecular structure, IM-250 may have a potential to disrupt the current market dynamic of HSV-related diseases.”, according to Thomas Hoffmann, co-founder & Managing Director at Innovative Molecules.
About Innovative Molecules
Innovative Molecules GmbH is a drug development company based in Munich, Germany. With the aim to set a new treatment standard for herpes simplex induced diseases, the company is focused on the development of IM-250, a potent, second-generation helicase-primase inhibitor of HSV-1 and HSV-2. For more information visit www.innovativemolecules.com
Copyright © 2016 - 2023 Innovative Molecules. Developed by Workshop Agency